论文部分内容阅读
急性心肌梗死(acute myocardial infarction,AMI)是心血管疾病中最危重的急性事件。抗栓治疗在显著降低非ST段抬高型心肌梗死(non-ST segment elevation myocardial infarction,NSTEMI)患者主要心血管事件的同时,增加了出血风险[1-2]。研究表明,出血发生率与患者远期预后呈正相关[3]。2011年欧洲心脏病协会年会新公布的NSTEMI治疗指南推荐采用CRUSADE评分评估
Acute myocardial infarction (AMI) is the most critical acute event in cardiovascular disease. Antithrombotic therapy increases the risk of bleeding while significantly reducing major cardiovascular events in patients with non-ST segment elevation myocardial infarction (NSTEMI) [1-2]. Studies have shown that the incidence of bleeding and prognosis of patients with a positive correlation [3]. The 2011 NSTEMI guidelines announced at the annual meeting of the European Society of Cardiology recommend the CRUSADE score assessment